Antimicrobial Resistance in Gram-Negative Bacterial Pneumonia After the COVID-19 Pandemic in Northern Iran
Golnar Rahimzadeh1, Mahdieh Askari2, Raha Rezai1
1Pediatric Infectious Diseases Research Center, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran.
Background:
The irrational use of antibiotics has become a significant factor in the escalating global crisis of antimicrobial resistance (AMR). AMR is linked to an increasing burden of healthcare-associated infections caused by multidrug-resistant pathogens, which present substantial challenges for infection control and patient management. During the COVID-19 pandemic, the widespread use of antibiotics for treating and preventing secondary bacterial infections further exacerbated the threat of AMR worldwide. This study aimed to determine the antibiotic resistance profile of Gram-negative bacteria (GNB) causing pneumonia after COVID-19 in Northern Iran.
Materials And Methods:
In this cross-sectional study, respiratory specimens were collected from hospitalized patients with bacterial pneumonia at four hospitals in Northern Iran. The antimicrobial susceptibility profiles were assessed using the standard microdilution method in accordance with CLSI guidelines (2020). Additionally, resistance-associated genetic determinants were evaluated using multiplex PCR.
Results:
A total of 120 MDR GNB isolates were identified, primarily from sputum specimens (75.8%). Pseudomonas aeruginosa was the most common pathogen in the ICU, representing 35% of isolates. Resistance rates to antibiotics were high: Ciprofloxacin (85%), Ceftazidime (85%), Gentamicin (80%), and Colistin (77.5%), while Piperacillin-Tazobactam had a lower resistance rate of 33.3%.
Conclusions:
The present study highlights the increasing AMR among GNB causing pneumonia in ICU settings post COVID-19 pandemic in hospitals in Northern Iran. The prevalence of Pseudomonas aeruginosa and high resistance rates to new antibiotics such as Colistin pose significant challenges to treatment, while Piperacillin-Tazobactam shows relatively lower resistance and may be a potential option.
Insights
Antimicrobial resistance (AMR) is a growing threat. This study found high rates of antibiotic resistance in Gram-negative bacteria causing pneumonia post-COVID-19 in Iran, with Piperacillin-Tazobactam showing lower resistance.
Area of Science:
- Medical Microbiology
- Infectious Diseases
- Public Health
Background:
- The irrational use of antibiotics fuels antimicrobial resistance (AMR), a global health crisis.
- Multidrug-resistant pathogens cause challenging healthcare-associated infections.
- Antibiotic use during the COVID-19 pandemic worsened the AMR threat.
Purpose of the Study:
- To determine the antibiotic resistance profile of Gram-negative bacteria (GNB) causing pneumonia in Northern Iran after the COVID-19 pandemic.
Main Methods:
- Collected respiratory specimens from hospitalized pneumonia patients in Northern Iran.
- Assessed antimicrobial susceptibility using microdilution (CLSI guidelines).
- Evaluated resistance-associated genes via multiplex PCR.
Main Results:
- Identified 120 multidrug-resistant (MDR) GNB isolates, mainly from sputum.
- Pseudomonas aeruginosa was the most common ICU pathogen (35%).
- High resistance rates observed for Ciprofloxacin (85%), Ceftazidime (85%), Gentamicin (80%), and Colistin (77.5%).
- Piperacillin-Tazobactam showed a lower resistance rate (33.3%).
Conclusions:
- AMR is increasing among GNB causing post-COVID-19 pneumonia in Northern Iran ICUs.
- Prevalence of Pseudomonas aeruginosa and high resistance to Colistin present treatment challenges.
- Piperacillin-Tazobactam's lower resistance suggests potential therapeutic utility.
More Related Videos
06:42Author Spotlight: Exploring the Antibacterial Effects of Zinc Oxide Nanoparticles in Overcoming Antibiotic Resistance
Published on: September 27, 2024
07:46Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung
Published on: June 5, 2012
Related Concept Videos
Antimicrobial Effectiveness
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Development of Antibiotic Resistance
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia III: Complications and Assessment
Pneumonia II: Pathophysiology
